ReShape Lifesciences Inc RSLS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 16, 2024 (filed on Jan 16, 2024)

Insider Name:

Schneid Yair

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 25, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-131

Price:

$0.27
Oct 11, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39

Price:

$0.93
Sep 01, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-118

Price:

$0.89
Aug 24, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39

Price:

$1.42
Aug 04, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-108

Price:

$1.43
Jul 06, 2023 (filed on Jul 19, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-106

Price:

$1.47
Jun 30, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

17,702

Price:

$1.52
May 31, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-98

Price:

$2.41
Apr 30, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-96

Price:

$2.36

Filings by filing date

Jan 16, 2024 (filed on Jan 16, 2024)

Insider Name:

Schneid Yair

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Oct 25, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-131

Price:

$0.27
Oct 11, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39

Price:

$0.93
Sep 01, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-118

Price:

$0.89
Aug 24, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39

Price:

$1.42
Aug 04, 2023 (filed on Nov 08, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-108

Price:

$1.43
Jul 06, 2023 (filed on Jul 19, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-106

Price:

$1.47
Jun 30, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

17,702

Price:

$1.52
May 31, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-98

Price:

$2.41
Apr 30, 2023 (filed on Jul 06, 2023)

Insider Name:

Stankovich Thomas

Ownership Type:

Direct Ownership

Securities:

Common Stock, $0.001 par value per share

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-96

Price:

$2.36

News

Biz Brief

Sector: Healthcare	Industry: Advanced Medical Equipment & Technology

See Regulatory Filings on SEC

Company Contact

Address:	1001 CALLE AMANECER SAN CLEMENTE CA 92673
Tel:	1-949-2766042
Website:	https://www.reshapelifesciences.com/obalon
IR:	See website

Key People

Dan W. Gladney Executive Chairman of the Board	Paul F. Hickey President, Chief Executive Officer, Director	Thomas Stankovich Chief Financial Officer

Business Overview

ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.

Financial Overview

For the fiscal year ended 31 December 2023, ReShape Lifesciences Inc revenues decreased 23% to $8.7M. Net loss decreased 75% to $11.4M. Revenues reflect United States segment decrease of 23% to $7.1M, Europe segment decrease of 24% to $956K, United States segment decrease of 23% to $7.1M, Europe segment decrease of 24% to $956K. Lower net loss reflects Sales and marketing - Balancing value decrease of 46% to $7.4M (expense), Selling.

Employees:	31 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$8.68M as of Dec 31, 2023
EBITDA (TTM):	-$14.48M as of Dec 31, 2023
Net annual income (TTM):	-$11.39M as of Dec 31, 2023
Free cash flow (TTM):	-$17.00M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	23,457,090 as of Mar 26, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization